CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS

• US 20100055101A1
• Filed: 08/21/2009
• Published: 03/04/2010
• Est. Priority Date: 01/18/2002
• Status: Abandoned Application

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Dillon, Stacey R., Novak, Julia E., Gross, Jane A., Sprecher, Cindy A., Whitmore, Theodore E., Hammond, Angela K., Grant, Francis J., Kuijper, Joseph L., Dasovich, Maria M.
• Application Number:
  US12/545,770
• Publication Number:
  US 20100055101A1
• Time in Patent Office: Days
• US Class Current: 424/134.100
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 39/02 : Antidotes
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/52 : Cytokines; Lymphokines; Interferons
• CPC Class Codes: C07K 14/715 : for cytokines; for lymphokines; for interferons
• CPC Class Codes: C07K 16/2866 : against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.

Claims

1. An isolated heterodimeric or multimeric receptor polypeptide comprising a first receptor polypeptide the amino acid sequence of which has at least 95% sequence identity with amino acid residues 20-732 of SEQ ID NO:

111, and a second receptor polypeptide comprising amino acid residues 28-979 of SEQ ID NO;

7, and wherein the heterodimeric or multimeric receptor polypeptide binds a ligand comprising amino acid residues 27-164 of SEQ ID NO;

2.

2. The isolated heterodimeric or multimeric receptor polypeptide of claim 1 wherein the receptor polypeptide comprises amino acid residues 20-732 of SEQ ID NO:

111.

3. The isolated heterodimeric or multimeric receptor polypeptide of claim 1 wherein the second receptor polypeptide comprises amino acid residues 28-979 of SEQ ID NO:

7.

4. An isolated soluble heterodimeric or multimeric receptor polypeptide comprising a first receptor polypeptide the amino acid sequence of which has at least 95% sequence identity with amino acid residues 20-519 of SEQ ID NO:

1, and a second receptor polypeptide comprising amino acid residues 28-739 of SEQ ID NO;

7, and wherein the soluble heterodimeric or multimeric receptor binds a ligand comprising amino acid residues 27-164 of SEQ ID NO;

2.

5. The isolated soluble heterodimeric or multimeric receptor polypeptide of claim 4 wherein the receptor polypeptide comprises amino acid residues 20-519 of SEQ ID NO:

111.

6. The isolated soluble heterodimeric or multimeric receptor polypeptide of claim 4 wherein the soluble heterodimeric or multimeric receptor comprises an immunoglobulin heavy chain constant region.

7. The isolated soluble heterodimeric or multimeric receptor polypeptide of claim 6 wherein the immunoglobulin heavy chain constant region is an F_c fragment.

8. A composition comprising:

a soluble heterodimeric or multimeric receptor polypeptide comprising a first receptor polypeptide the amino acid sequence of which has at least 95% sequence identity with amino acid residues 20-519 of SEQ ID NO;

111, and a second soluble receptor polypeptide comprising amino acid residues 28-739 of SEQ ID NO;

7; and

a pharmaceutically acceptable vehicle.

9. The composition of claim 8 wherein the soluble heterodimeric or multimeric receptor polypeptide is fused to an immunoglobulin heavy chain constant region.

10. The composition of claim 9 wherein the immunoglobulin heavy chain constant region is an F_c fragment.

11. An isolated heterodimeric or multimeric receptor polypeptide comprising a first receptor polypeptide comprising amino acid residues 20-732 of SEQ ID NO:

111, and a second receptor polypeptide comprising amino acid residues 28-979 of SEQ ID NO;

7.

12. The isolated heterodimeric or multimeric receptor polypeptide of claim 11 wherein the receptor polypeptide comprises amino acid residues 1-732 of SEQ ID NO:

111.

13. The isolated heterodimeric or multimeric receptor polypeptide of claim 11 wherein the second receptor polypeptide comprises amino acid residues 1-979 of SEQ ID NO:

7.

14. An isolated soluble heterodimeric or multimeric receptor polypeptide comprising a first receptor polypeptide comprising amino acid residues 20-519 of SEQ ID NO:

111, and a second soluble receptor polypeptide comprising amino acid residues 28-739 of SEQ ID NO;

7.

15. The isolated soluble heterodimeric or multimeric receptor polypeptide of claim 14 wherein the soluble heterodimeric or multimeric receptor polypeptide antagonizes an activity of the ligand comprising amino acid residues 27-164 of SEQ ID NO:

2.

16. The isolated soluble heterodimeric or multimeric receptor polypeptide of claim 14 wherein the soluble multimeric or heterodimeric receptor inhibits proliferation of CD4+ cells, inhibits proliferation of CD19+ cells, inhibits proliferation of inflammatory cells, or inhibits an inflammatory response.

17. The isolated soluble heterodimeric or multimeric receptor polypeptide of claim 14 wherein the soluble multimeric or heterodimeric receptor comprises an immunoglobulin heavy chain constant region.

18. The isolated soluble heterodimeric or multimeric receptor polypeptide of claim 17 wherein the immunoglobulin heavy chain constant region is an Fc fragment.

19. A composition comprising:

a soluble heterodimeric or multimeric receptor polypeptide comprising a first receptor polypeptide comprising amino acid residues 20-519 of SEQ ID NO;

111, and a second soluble receptor polypeptide comprising amino acid residues 28-739 of SEQ ID NO;

7; and

a pharmaceutically acceptable vehicle.

20. The composition of claim 19 wherein the soluble heterodimeric or multimeric receptor polypeptide is fused to an immunoglobulin heavy chain constant region.

21. The composition of claim 20 wherein the immunoglobulin heavy chain constant region is an Fc fragment.